530233 — Auro Laboratories Share Price
0.000.00%
Last trade - 00:00- IN₹1.07bn
- IN₹1.24bn
- IN₹536.35m
- 62
- 51
- 69
- 68
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.88 | ||
| Price to Tang. Book | 2.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.25 | ||
| EV to EBITDA | 12.92 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.5% | ||
| Return on Equity | 20.46% | ||
| Operating Margin | 17.86% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 437.91 | 542.52 | 508.66 | 528.94 | 536.35 | n/a | n/a | 2.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -7.84 | +77.08 | -60.38 | -14.16 | +219.09 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Auro Laboratories Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs), intermediates and generic formulations. The Company operates through the Pharmaceuticals segment. It offers APIs under categories, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids anti-inflammatory and others. Its products under intermediates include Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, 2-Ethoxy Benzoic Acid, 3,4,5, Trimethoxy Benzoic Acid and 5-Bromo Phthalide. It also undertakes toll/custom manufacturing for APIs and Intermediates on contract basis. The Company has a presence in international markets with bulk of its production being exported to Southeast Asia, Middle East and several European Countries. Some of the countries it exports to are Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom.
Directors
- Sharat Deorah CHM
- Seshdhar Dubey CCO
- Siddhartha Deorah EDR
- Kiran Kulkarni EDR (49)
- Kavita Sharma IND
- Goverdhandas Aggarwal NID
- Kailash Bubna NID (58)
- Last Annual
- March 31st, 2024
- Last Interim
- March 31st, 2024
- Incorporated
- May 26th, 1989
- Public Since
- March 7th, 1995
- No. of Employees
- 66
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Bombay Stock Exchange
- Shares in Issue
- 6,232,500
- Address
- 314, S.K. AHIRE MARG, MUMBAI, 400030
- Web
- http://www.aurolabs.com/
- Phone
- +91 2266635456
- Auditors
- KOTHARI JAIN & ASSOCIATES
Upcoming Events for 530233
Q1 2025 Auro Laboratories Ltd Earnings Release
Q2 2025 Auro Laboratories Ltd Earnings Release
Similar to 530233
Achyut Healthcare
Bombay Stock Exchange
Adline Chem Lab
Bombay Stock Exchange
MPS Pharmaa
Bombay Stock Exchange
Albert David
Bombay Stock Exchange
Ambalal Sarabhai Enterprises
Bombay Stock Exchange
FAQ
What is the Auro Laboratories share price?
As of Today at 13:27 UTC, shares in Auro Laboratories are trading at IN₹193.95. This share price information is delayed by 15 minutes.
How has the Auro Laboratories share price performed this year?
Shares in Auro Laboratories last closed at IN₹193.95 and the price had moved by +120.37% over the past 365 days. In terms of relative price strength the Auro Laboratories share price has outperformed the S&P BSE 100 Index by +69.74% over the past year.
What are the analyst and broker recommendations for Auro Laboratories?
There is no consensus recommendation for this security.
What is the Auro Laboratories dividend yield?
Auro Laboratories does not currently pay a dividend.
Does Auro Laboratories pay a dividend?
Auro Laboratories does not currently pay a dividend.
When does Auro Laboratories next pay dividends?
Auro Laboratories does not currently pay a dividend.
How do I buy Auro Laboratories shares?
To buy shares in Auro Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Auro Laboratories?
As of the previous close price of IN₹193.95, shares in Auro Laboratories had a market capitalisation of IN₹1.21bn.
Where are Auro Laboratories shares listed?
Here are the trading details for Auro Laboratories:
- Country of listing: India
- Exchange: BSE
- Ticker Symbol: 530233
What kind of share is Auro Laboratories?
Based on an overall assessment of its quality, value and momentum Auro Laboratories is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Auro Laboratories share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Auro Laboratories share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Auro Laboratories. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +52.86%.
As of the last closing price of IN₹193.95, shares in Auro Laboratories were trading +25.39% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Auro Laboratories PE Ratio?
The Auro Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹193.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Auro Laboratories?
Auro Laboratories' management team is headed by:
- Sharat Deorah - CHM
- Seshdhar Dubey - CCO
- Siddhartha Deorah - EDR
- Kiran Kulkarni - EDR
- Kavita Sharma - IND
- Goverdhandas Aggarwal - NID
- Kailash Bubna - NID